Aservo® EquiHaler®, Industry-first Therapy For Severe Equine Asthma, Now Available In The UK And Ireland
- Aservo®EquiHaler® addresses an unmet need in the equine market
- Aservo®EquiHaler® (ciclesonide inhalation solution) is a result of synergies between human pharma and animal health businesses to make Soft Mist™ technology available for
- Boehringer Ingelheim (BI) continues to set new standards of care to strengthen its commitment to animal welfare
Equine Asthma is the most common respiratory disease in horses. It can have a significant impact on performance and quality of life for affected animals. From today, horses that suffer from severe equine asthma can now benefit from Aservo® EquiHaler® – the first inhaled treatment approved for use in horses.
The development of Aservo® EquiHaler® by BI Animal Health Research & Development team has taken over 10 years and has been the result of a collaboration with BI’s Human Pharma business, using their Respimat™ inhaler technology. The Respimat™ inhaler used in human respiratory disease is characterised by the Soft Mist™ technology, which was integrated into the new Aservo® EquiHaler®, allowing medication to be inhaled deep into the horses' lungs. The active ingredient in the Aservo® EquiHaler® is ciclesonide, which is a corticosteroid that is activated directly in the lung, reducing the lower airway inflammation associated with severe equine asthma and reducing the risks commonly associated with systemic corticosteroids.
Dr Marc Laemmer, Head of Equine in UK & Ireland said: "It's another industry first and is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation. We understand that a product launch in this challenging time for the veterinary profession may seem surprising, but we have had such strong demand from equine vets for the product that we have committed to making Aservo® EquiHaler® available. Out team of territory managers and vet advisers will conduct remote meetings with customers to make sure that they have the information and support they require.
The launch of Aservo® EquiHaler® is a prime example of leveraging innovation efforts of both our human and animal businesses. This has been a strength of ours and I'm excited that we are continuing to further increase the delivery of innovative solutions for horse owners and vets."
No harmful greenhouse gas emissions
With such an innovative new product, it is critical to not only consider the technology, but the sustainability too. As Aservo® EquiHaler® uses the same Soft Mist™ Technology in the human Respimat™ inhaler, it does not use a propellant, which means that using the device does not contribute to harmful greenhouse gas emissions. Aservo® EquiHaler® has been manufactured from up to 50% recycled materials – a real development for our market.
Awarded the Red Dot Award for outstanding design
Aservo® EquiHaler® includes an ergonomic handle and dosing lever for ease of user handling, and a nostril adaptor that fits gently inside the nostril of the horse, allowing them to easily inhale the medicated mist.
It is because of these particular design features that in April this year, Aservo® EquiHaler® was awarded the prestigious Red Dot Award for Product Design.
Today (22 June) Aservo® EquiHaler® will be added to the exhibition
“Design on Stage” in the Red Dot Design Museum, where all of the award-winning products are expected to be on display. The museum will be a hot spot for best-in-class industrial design. Aservo® EquiHaler® will also be presented in the online exhibition on the Red Dot website. The Red Dot Design Yearbook 2020/2021 comes out in July 2020.
About Red Dot
The Red Dot is an international competition which originated more than 60 years ago, offering designers and manufacturers from all over the world a platform for evaluating quality for good design of their products. In 2020, designers and companies from 60 countries submitted more than 6,500 products in the competition. The international jury comprises experienced experts from different disciplines and convenes to test, discuss and assess each individual entry without any preselection in order to select the best designs of the year. The adjudication process lasts several days and is based on essential criteria: the jurors test all of the entries in order to assess not just the aesthetic but also the materials selected, the level of craftsmanship, the surface structure, ergonomics and functionality.
Aservo® EquiHaler® contains ciclenoside. UK: POM-V IE: POM. Further information available in the SPC. UK Tel: 01344 746960 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Email:vetenquiries@boehrin ger-ingelheim.com. Aservo® EquiHaler® are registered trademarks of Boehringer Ingelheim Vetmedica GmbH, used under licence. ©2020 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Jun 2020. UI-EQU-0126-2020. Use Medicines Responsibly.
More from Boehringer Ingelheim
- Boehringer Ingelheim launch first POM-V medicine recycling programme for UK equine veterinary practices
- Boehringer Ingelheim steps up to help puppy parent boomers
- BI Animal Health launches social media 'how-to' guides
- A heartfelt THANK YOU to all equine vets
- Vet nurses win lifestyle subscription boxes in NexGard Spectra competition